Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01809717 · ClinicalTrials.gov registry record · NA
Multiple Myeloma and Exercise
A NA study of Newly Diagnosed Multiple Myeloma, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01809717: Completed NA study of Newly Diagnosed Multiple Myeloma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01809717 is a NA study of Newly Diagnosed Multiple Myeloma that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01809717, a NA study of Newly Diagnosed Multiple Myeloma, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.
Conditions Studied
Interventions
- OTHER Weight Lifting Exercises
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the Unviersity of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-08 |
| Phase | NA |
What the finished NCT01809717 record still lists
NCT01809717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Newly Diagnosed Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Weight Lifting Exercises is the first listed.
NCT01809717 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01809717 about?
NCT01809717 is a clinical study titled "Multiple Myeloma and Exercise". This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.
What is the current status of trial NCT01809717?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2013-03. Estimated completion is 2013-08.
What conditions does trial NCT01809717 study?
This clinical trial studies the following conditions: Newly Diagnosed Multiple Myeloma.
What interventions are being tested in trial NCT01809717?
The interventions under investigation include: Weight Lifting Exercises (OTHER).
Who is sponsoring clinical trial NCT01809717?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01809717 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Newly Diagnosed Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01809717's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RECRUITING · Phase 3
-
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia